ReviewFrontiers in immunology2026
Awakening antitumour immunity in the multimorbid host: a hypothesis coupling cryoablation-induced immunogenic cell death with multi-target Traditional Chinese Medicine.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most patients with cancer are older adults living with several other chronic illnesses, and both the tumour and its commonest companions-cardiometabolic disease, type 2 diabetes and depression-are sustained by a shared, immunosuppressive inflammatory milieu. In this setting many tumours are immunologically "cold": poorly infiltrated by cytotoxic T and natural killer (NK) cells, enriched for regulatory T cells (Tregs) and M2 macrophages, and embedded in a chronically inflamed "soil" that also drives the comorbidities. Here we advance a mechanistic hypothesis: that two low-harm modalities applied together can reawaken antitumour immunity in this host while sparing the physiological reserve that radical treatment consumes. Minimally invasive cryoablation destroys tumour
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.